Management of cesarean delivery in a parturient with sickle cell disease

Romano, Diana; Craig, H. Randall; Katz, Daniel

doi:10.1016/j.ijoa.2019.09.001

Cited by 4 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The more common coagulopathic presentation of systemic autoimmune diseases is a hypercoagulable state. It is well described that systemic lupus erythematosus patients can develop specific antibodies such as lupus anticoagulant, antiphospholipid syndrome, antiprothrombin, and No abnormal variables documented CT: # 154,155 CFT: # [154][155][156] A: " 155 MCF: " [154][155][156][157] VET variables were more hypercoagulable in splenectomized thalassemic patients compared to nonsplenectomized 154,156,157 There is no predisposition to hypercoagulability in children with hereditary spherocytosis unless the child has had a splenectomy 158 Sickle cell disease R: # [159][160][161] K: # 160,161 A: " 159,160 MA: " 159,160 CI: " 159,160 CT: # 162 MCF: " 162,163 Sickle 162,163 No difference in VET variables between SCT and NC 161 Treatments guided by VETs:…”

Section: Systemic Autoimmune Diseasesmentioning

confidence: 99%

“…• Heparin/protamine 162,163 • Chronic transfusion therapy 159 • Exchange blood transfusion 160 • Hydroxyurea therapy 159 • Hydroxycarbamide 160 • Ameliorating therapy 160 HbSC anticardiolipin; these antibodies often result in coagulopathies. These antibodies or the disease itself pose a risk for venous thomboembolic events and pregnancy-related complications.…”

Section: Systemic Autoimmune Diseasesmentioning

confidence: 99%

“…Pregnant sickle cell patients who anticoagulated during pregnancy required ROTEM guided reversal of LMWH and unfractionated heparin because the patients were unexpectedly hypercoagulopathic 162,163 …”

Section: Benign Hematologic Disordersmentioning

confidence: 99%

“…Treatments guided by VETs: Heparin/protamine 162,163 Chronic transfusion therapy 159 Exchange blood transfusion 160 Hydroxyurea therapy 159 Hydroxycarbamide 160 Ameliorating therapy 160 …”

Section: Benign Hematologic Disordersmentioning

confidence: 99%

See 3 more Smart Citations

Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point‐of‐care testing to assess hemostatic competence

et al. 2020

View full text Add to dashboard Cite

Viscoelastic tests (VETs) have been used routinely for liver transplantation, cardiac surgery, and trauma, but only recently have found clinical utility in benign hematologic disorders. Therefore, guidelines for diagnosis and treatment of these disorders based on viscoelastic variables have been adapted from the existing transplant, cardiothoracic surgery, and trauma resuscitation literature. As a result, diagnostic and therapeutic strategies for benign hematologic disorders utilizing VETs are not uniform. Accordingly, even though there has been a recent increase in the utilization of VET for the diagnosis and treatment of such disorders, the literature is still in its early stages. Analysis of point‐of‐care viscoelastic tracings from benign hematologic disorders has the potential to allow prompt recognition of disease and to guide patient‐specific intervention. Here we present a review describing the application of VETs to benign hematologic disorders.

show abstract

Section: Systemic Autoimmune Diseasesmentioning

confidence: 99%

Section: Systemic Autoimmune Diseasesmentioning

confidence: 99%

Section: Benign Hematologic Disordersmentioning

confidence: 99%

“…Treatments guided by VETs: Heparin/protamine 162,163 Chronic transfusion therapy 159 Exchange blood transfusion 160 Hydroxyurea therapy 159 Hydroxycarbamide 160 Ameliorating therapy 160 …”

Section: Benign Hematologic Disordersmentioning

confidence: 99%

See 2 more Smart Citations

Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point‐of‐care testing to assess hemostatic competence

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These antibodies are difficult to detect during routine antibody screening [29,30]. It is known that the presence of these alloantibodies or autoantibodies makes future transfusions unsafe due to higher risks of haemolytic transfusion reactions [31].…”

Section: Previous Transfusionmentioning

confidence: 99%

Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs

2020

View full text Add to dashboard Cite

Sickle cell anaemia presents with a dynamic background haemolysis and deepening anaemia. This increases the demand for transfusion if any additional strain on haemopoiesis is encountered due to any other physiological or pathological. Patients with cerebrovascular accident are placed on chronic blood transfusion; those with acute sequestration and acute chest syndrome are likewise managed with blood transfusion. These patients are prone to develop blood transfusion complications including alloimmunization and hyperhaemolytic syndrome (HHS). This term is used to describe haemolysis of both transfused and ‘own’ red cells occurring during or post-transfusion in sickle cell patients. Hyperhaemolysis results in worsening post-transfusion haemoglobin due attendant haemolysis of both transfused and autologous red cells. The mechanism underlying this rare and usually fatal complication of sickle cell has been thought to be secondary to changes in the red cell membrane with associated immunological reactions against exposed cell membrane phospholipids. The predisposition to HHS in sickle cell is also varied and the search for a prediction pattern or value has been evasive. This review to discusses the pathogenesis, risk factors and treatment of hyperhaemolytic syndrome, elaborating what is known of this rare condition.

show abstract

Disorders of Blood, Coagulation, and Bone Marrow

Brown,

Douglas

2024

Obstetric Anesthesia and Uncommon Disorders

View full text Add to dashboard Cite

Management of cesarean delivery in a parturient with sickle cell disease

Cited by 4 publications

References 18 publications

Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point‐of‐care testing to assess hemostatic competence

Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point‐of‐care testing to assess hemostatic competence

Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs

Disorders of Blood, Coagulation, and Bone Marrow

Contact Info

Product

Resources

About